Oral transmucosal fentanyl citrate: a novel agent for breakthrough pain related to cancer
Authors:
- Erin McMenaminEMErin McMenamin
- John T FarrarJFJohn T Farrar
- 1 September 2002
- journal article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 2 (5) , 625-629
Abstract
Pain is problematic for many cancer patients. As more experience has been gained in treating cancer pain, breakthrough pain has been recognized as a phenomenon that occurs frequently in this population. Breakthrough pain is generally treated with a variety of short-acting opioids via a number of routes. Actiq (oral transmucosal fentanyl citrate) is a formulation of fentanyl citrate delivered via the transmucosal route in a sucrose base. Patients using this agent are instructed to paint the unit on the buccal mucosa in order to achieve relief. The onset of Actiq is reported to be equal to intravenous morphine. There are a wide variety of dosage forms available, allowing 74% of patients involved in clinical studies of the agent to titrate to an appropriate dose. The proper use, side effect profile and advantages/disadvantages will be reviewed for this agent.Keywords
This publication has 11 references indexed in Scilit:
- Symptom control in cancer patients: the clinical pharmacology and therapeutic role of suppositories and rectal suspensionsSupportive Care in Cancer, 2002
- Episodic (breakthrough) painCancer, 2002
- Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)Pain, 2001
- Multiple Dose Pharmacokinetics of Oral Transmucosal Fentanyl Citrate in Healthy VolunteersAnesthesiology, 2000
- The Relative Potency of Oral Transmucosal Fentanyl Citrate Compared with Intravenous Morphine in the Treatment of Moderate to Severe Postoperative PainAnesthesia & Analgesia, 1999
- Breakthrough pain: characteristics and impact in patients with cancer painPain, 1999
- Oral transmucosal fentanyl citrate: A new treatment for breakthrough painAmerican Journal of Hospice and Palliative Medicine®, 1999
- Cancer pain management: Newer perspectives on opioids and episodic painAmerican Journal of Hospice and Palliative Medicine®, 1998
- Absorption and Bioavailability of Oral Transmucosal Fentanyl CitrateAnesthesiology, 1991
- Breakthrough pain: definition, prevalence and characteristicsPain, 1990